The acquired assets comprise the NovaCross family of microcatheters, including NovaCross CTO, NovaCross Xtreme and NovaCross BTK.
These devices enable the intraluminal placement of conventional and steerable guidewires beyond stenotic lesions, including chronic total occlusions (CTO), before percutaneous transluminal coronary angioplasty (PTCA) or stent intervention.
The NovaCross microcatheter family can be used as standalone devices or incorporated into Microbot Medical’s One & Done technology. They are also anticipated to form a collection of customised procedure-related kits for the LIBERTY Robotic System.
Designed to lower capital investment requirements and Cath Lab space, the LIBERTY Robotic System is claimed to be the first-ever disposable endovascular robotic system with remote operation capabilities.
The acquisition of technologies such as the NovaCross Microcatheter family is expected to help Microbot Medical expand its market share in robotics and instruments for endovascular procedures. In the future, the company also aims to use the products to integrate imaging and big data capabilities.
Microbot Medical chairman, president and CEO Harel Gadot said: “The addition of Nitiloop’s innovative, FDA-cleared microcatheter family complements the unique robotic ecosystem we are establishing for endovascular procedures.
“This is expected to further assist us in executing our strategic plan of becoming a complete procedure-based company, allowing Microbot Medical to be competitive across the entire endovascular robotic space.
“We believe the NovaCross family of products, once integrated into our existing technology platforms with the LIBERTY Robotic System and our future One & Done technology, will potentially standardise endovascular procedures globally and may finally allow accessibility to robotic technology for the millions that are in dire need of life-saving treatment.”